Compounding of sterile corticotropin solutions for adrenal function testing in companion animal practice is configured around low-pH buffered aqueous vehicles, aseptic filtration, and lyophilization rather than terminal sterilization. The peptide is surface-active and adsorbs to uncoated glass and polypropylene, so bulk solution hold vessels are either low-protein-binding polyethylene terephthalate glycol or type I borosilicate glass with silicon dioxide coating. Sterilizing filtration is performed through double-layer polyethersulfone capsule filters with a nominal pore size of 0.22 µm; terminal steam sterilization at 121 °C for 15 min is excluded because aggregation and hydrolytic fragments increase outside compendial specification limits. Bulk solution is held at 2–8 °C and filled within a validated maximum hold period, commonly not exceeding 6–8 h from filter integrity test to stoppering. Filling is executed on peristaltic or rotary piston equipment inside an isolator or restricted-access barrier system with continuous viable and non-viable particle monitoring. Endotoxin control relies on USP <85> or Ph. Eur. 2.6.14, sterility on USP <71> or Ph. Eur. 2.6.1, subvisible particulate matter on USP <788>, and compounding workflow on USP <797> or Ph. Eur. 5.1. The finished dosage form is usually a lyophilized powder for reconstitution with sterile 0.9% w/v sodium chloride injection immediately before intravenous or intramuscular administration. Ready-to-use liquid presentations are constrained by short cold-chain shelf life and are generally reserved for hospital preparation rather than distribution.

What Are the Critical Freeze-Drying Boundaries for Corticotropin Injection Vials?

Lyophilization of corticotropin is a deep-dive zone because the collapse temperature is generally below common shelf temperatures, and vial-to-vial heat transfer differences create visible cake defects. Production-scale freeze dryers are programmed with shelf mapping across top, middle, and bottom radiators, and cycle development uses product temperature probes and comparative pressure measurement to detect primary drying endpoint. The glass transition temperature of the maximally freeze-concentrated solute can fall within a narrow band; collapse is managed by holding product temperature below that threshold even when shelf temperature ramps upward. A conservative cycle uses a freezing ramp to -45 °C or lower, a primary drying shelf temperature of -25 °C to -15 °C at chamber pressure 50–120 µbar, and secondary drying at +25 °C to +40 °C for 4–12 h. Residual moisture is controlled to <1.0% w/w because higher residual water accelerates methionine oxidation and deamidation during storage. Cake collapse, melt-back, and fogging are failure modes observed when chamber pressure is reduced too early or when the shelf ramp exceeds the glass transition. Batch release includes visual inspection, differential scanning calorimetry or freeze-drying microscopy on engineering runs, and stability-indicating reversed-phase HPLC with peptide mapping. The following process limits are representative for a production-scale lyophilizer with a clean-in-place and steam-in-place freeze dryer chamber.

For long-acting injectable suspensions used in referral equine and bovine practice, the processing route differs from lyophilized vial manufacture because the peptide is bound to zinc salts or suspended in carboxymethylcellulose sodium and poloxamer vehicles, which reduces rapid renal clearance and prolongs adrenal stimulation. Aseptic precipitation or adsorption of corticotropin onto zinc hydroxide particles is performed in a jacketed reactor at 2–8 °C. Homogenization is carried out with a high-shear rotor-stator mixer, for example a Silverson L5M-A, at 3,000–6,000 rpm for initial dispersion, followed by particle-size verification by laser diffraction. The finished suspension is filled through a positive-displacement pump with gentle agitation to maintain homogeneity. Syringeability is measured by the force required to extrude through a 21 G needle; a maximum of 20 N is often applied as an upper processing target in injectable suspension development. Viscosity is controlled within 50–200 cP at 25 °C with the selected carboxymethylcellulose grade, and the vehicle includes isotonic sodium chloride and a preservative such as phenol or methylparaben, depending on the multidose claim. In food-producing animals, residue depletion must be assessed under Regulation (EC) No 470/2009 and any applicable national MRL database; if no MRL is published for the target species, the product is not suitable for food-producing uses.

Cold-Chain API Handling and Working Reference Standard Potency Assignments

In veterinary quality control laboratories, corticotropin API is handled as a lyophilized or frozen bulk peptide with assigned biological potency in International Units per milligram. The working standard is prepared from the pharmacopoeial reference standard and qualified by bioassay, not by chromatographic peak area alone, because peptide fragments may retain absorbance but lose adrenal-stimulating activity. Storage is maintained at -20 °C or lower under desiccant and inert gas, and the number of opening cycles is limited to reduce water uptake and oxidation. Weighing is performed in a guarded balance enclosure with relative humidity below 20% RH, because the API is hygroscopic and electrostatic. Bioassay validation includes dose-response parallelism, quantification at multiple dilution levels, and system suitability with reference preparations. Laboratory data supporting potency assignment are maintained under ISO/IEC 17025 or 21 CFR Part 58 GLP requirements, depending on whether the study is regulatory or internal. Potency values above the shelf-life update are not used for batch release; re-qualification is scheduled after any excursion above -15 °C for more than 24 h or after prolonged shipping.

When a Tablet or Capsule Route Is Requested Despite Native Peptide Instability

Converting native corticotropin to tablets, capsules, oral powders, granules, or premix introduces barriers that are not primarily compressibility but gastrointestinal instability and feed processing heat. Published bioavailability data for oral native ACTH in target species is limited; the peptide is cleaved by gastric pepsin, pancreatic trypsin, and brush-border peptidases, so conventional enteric coatings alone do not create systemic exposure. Wet granulation with water or hydro-alcoholic binder at 40–60 °C tray-drying is compatible with the dry powder only for non-aqueous granulation; aqueous granulation accelerates degradation unless the granulate is dried under vacuum to <2% w/w moisture. Tablet compression requires low compression force and may use brittle excipients such as anhydrous dicalcium phosphate; elastic recovery of the peptide-rich granules can cause capping. Capsule filling with lactose or mannitol is feasible for research batches but not for clinical systemic use because the peptide is not absorbed intact. Premix manufacturing in feed mills is limited by pelleting temperatures of 70–90 °C and steam conditioning, which destroys the peptide; post-pelleting vacuum coating or cold extrusion may be evaluated only for experimental local exposure. For all these routes, process validation requires content uniformity by USP <905>, stability data, and assay recovery, not merely blend uniformity. Without published pharmacokinetic evidence, such formulations cannot be promoted as systemic veterinary therapies.

When a ready-to-use solution is required for short-term hospital use, the formulation is constrained by aqueous hydrolysis, oxidation, and microbial proliferation rather than by the intrinsic potency of the API. Diluents are pre-cooled to 2–8 °C before reconstitution; normal saline is preferred over dextrose-containing fluids because reducing sugars accelerate Maillard-type modification of the peptide. The reconstituted solution is visually inspected for particulates and is administered through a low-protein-binding infusion set with a 0.2 µm in-line filter only if compatibility with the filter membrane is confirmed. Storage of the reconstituted vial beyond 24 h at 2–8 °C is not recommended in most compounding procedures because potency loss becomes variable and cannot be controlled by preservatives alone. Aqueous formulation development, if a ready-to-use solution is proposed, requires forced degradation studies at high temperature and pH, plus a preservative effectiveness test under USP <51> or Ph. Eur. 5.1.3 if multidose. However, for corticotropin veterinary injections, the more common commercially feasible product is lyophilized powder followed by extemporaneous reconstitution, not a ready-to-use solution.